Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Q3 2026 net loss narrows to $21.8 million; revenue falls to $8.5 million

Mixed Impact 3 of 5 earnings Written later

C4 Therapeutics reported third-quarter 2026 revenue of $8.5 million, down from $11.2 million a year earlier, as research activities tied to its Merck and Merck KGaA collaborations concluded. Net loss narrowed to $21.8 million, or $0.16 per share, from $32.2 million, or $0.44 per share, in the prior-year quarter, which included a $10.7 million impairment charge. The company said its cash runway extends to the end of 2028.

Key points

  • Q3 2026 revenue $8.5 million vs. $11.2 million in Q3 2025, driven by lower Merck and Merck KGaA research revenue, partly offset by Roche collaboration revenue
  • Q3 2026 net loss $21.8 million ($0.16 per share) vs. $32.2 million ($0.44 per share); Q3 2025 included a $10.7 million impairment of long-lived assets
  • Cash, cash equivalents and marketable securities were $274.7 million at September 30, 2026, vs. $300.4 million at June 30, 2026
  • Company expects current cash to fund its operating plan to the end of 2028; Phase 2 MOMENTUM trial enrollment expected to complete in 1Q 2027

The filing

CompanyC4 Therapeutics, Inc. (CCCC)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:15 AM ET
Accession number0001628280-26-070560

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.